Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials
Tobias Derfuß(University of Basel), Amit Bar‐Or(University of Pennsylvania), Licínio Craveiro(Roche (Switzerland)), Nikki Jessop(Roche (Switzerland)), Timothy Vollmer(Rocky Mountain MS Center), Ludwig Kappos(University Hospital of Basel), Hans‐Peter Hartung(The University of Sydney), Cathy Chognot(Roche (Switzerland)), Martin S. Weber(Fraunhofer Institute for Translational Medicine and Pharmacology), Jianmei Wang(Harbin Medical University), Chien‐Ju Lin(Kaohsiung Medical University), Robert A Bermel(Cleveland Clinic), Stephen L. Hauser(University of California, San Francisco), Gavin Giovannoni(Queen Mary University of London)
Cited by 23
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k